Ucb Inc patents expiration
1. Briviact patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6784197 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(3 years ago) | |
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492416 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(3 years ago) | |
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older
Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS
BRIVIACT family patents
2. Fintepla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947183 | UCB INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(9 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(11 years from now) | |
|
US10950331 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Mar, 2036
(11 years from now) | |
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(13 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(13 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(13 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(14 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| New Product(NP) | Jun 25, 2023 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...
Dosage: SOLUTION;ORAL
FINTEPLA family patents
3. Fluxid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6221392 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6024981 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Drugs and Companies using FAMOTIDINE ingredient
Market Authorisation Date: 24 September, 2004
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
FLUXID family patents
4. Kemstro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6221392 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6024981 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 30 October, 2003
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
KEMSTRO family patents
5. Keppra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(7 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 06 January, 2006
Treatment: NA
Dosage: TABLET;ORAL
KEPPRA family patents
6. Keppra Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 12, 2011 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
KEPPRA XR family patents
7. Nayzilam patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8809322 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US9289432 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US8217033 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US9687495 | UCB INC | Methods and systems for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-243) | May 17, 2026 |
| New Product(NP) | May 21, 2022 |
Drugs and Companies using MIDAZOLAM ingredient
Market Authorisation Date: 17 May, 2019
Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patie...
Dosage: SPRAY;NASAL
NAYZILAM family patents
8. Neupro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7413747 | UCB INC | Transdermal therapeutic system for treating Parkinsonism |
Mar, 2019
(5 years ago) | |
| US6699498 | UCB INC | Transdermal therapeutic systems having improved stability and their production |
Nov, 2020
(3 years ago) | |
| US6884434 | UCB INC | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar, 2021
(3 years ago) | |
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(8 months ago) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(1 year, 7 months from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(3 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-647) | Apr 02, 2015 |
| New Indication(I-646) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of s...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
9. Niravam patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6024981 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6221392 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Drugs and Companies using ALPRAZOLAM ingredient
Market Authorisation Date: 19 January, 2005
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NIRAVAM family patents
10. Vimpat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(9 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-188) | Apr 28, 2026 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Indication(I-878) | Nov 16, 2023 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of use for treatment of partial-onset seizures in patients 4 years of age a...
Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS; SOLUTION;ORAL
VIMPAT family patents
11. Zilbrysq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
Dosage: SOLUTION;SUBCUTANEOUS
ZILBRYSQ family patents